ReviewActa neuropathologica communications2025
New experimental therapies for glioblastoma: a review of preclinical research.
Review in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Design, synthesis and anti-glioblastoma multiforme activity of N-methoxy-2-(pyrimidin-4-ylamino)benzamide derivatives as focal adhesion kinase inhibitors.Molecular diversity · 2026Article
- Engineered Exosomes in Precision Neuro-Oncology: Mechanisms, Therapeutics, and Translational Challenges.Cancers · 2026Review
- Review
- Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology.Diagnostics (Basel, Switzerland) · 2026Review
- Dual-modal Fe-MOF-derived piezoelectric nanofibers enable combinatorial tumor suppression via tumor treating fields and magnetic hyperthermia.Science and technology of advanced materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most common and malignant glial tumor of the central nervous system with an incidence from 0.59 to 3.69 per 100 000 depending on the region. Patient prognosis remains poor, highlighting the urgent need for novel therapies. This review analyzes preclinical studies published in the past seven years, covering a broad spectrum of experimental therapies, including small molecules, energy-based interventions, immunotherapies, gene and cell-based treatments, and tumor microenvironment–targeting approaches. I evaluate therapeutic efficacy, experimental models, and translational potential, and discuss key limitations and opportunities in the current research landscape. Finally, I outline future directions to enhance the clinical relevance of preclinical findings and accelerate the development of effective therapies for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.